|

Withdrawal of Dupilumab in Severe Asthma

RECRUITINGPhase 4Sponsored by University Hospital, Toulouse
Actively Recruiting
PhasePhase 4
SponsorUniversity Hospital, Toulouse
Started2025-12-15
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months. Although data showed that safety and efficacy of dupilumab are sustained when treatment is extended up to 3 years, no study has emerged regarding dupilumab discontinuation. This study aims to demonstrate the non-inferiority regarding strategy failure at 24 months of stopping dupilumab (intervention group) compared with its continuation (control group) in controlled asthma patients receiving this drug for at least 3 years.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients ≥ 18 years old
* Treated with dupilumab for at least 36 months for severe asthma
* Well controlled asthma defined by an Asthma Control Questionnaire score ≥ 18 and 0 or 1 exacerbation within the year prior to the inclusion visit

Exclusion Criteria:

* Patients who refuse to discontinue dupilumab, for any reason
* Patients with Forced expiratory volume in one second ≤ 30% of predicted values
* Patients treated by an oral corticosteroid dose ≥ 10 mg/day (in prednisone equivalent)
* Patients who have to discontinue dupilumab for a reason other than controlled asthma, such as an adverse drug reaction, a planned or current pregnancy, or a planned switch to another biologic indicated in severe asthma
* Patients who have to continue dupilumab for the treatment of comorbidities apart from nasal polyposis
* Active smoking
* Pregnancy or breastfeeding

Conditions2

AsthmaSevere Asthma

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.